急性髓系白血病:2023年诊断、风险分层和治疗更新
本文综述了急性髓系白血病(AML)在2022年发布的两套分类系统、欧洲白血病网2022风险分层以及基于可测量残留病(MRD)的动态风险评估方面的进展,并提出了整合患者治疗目标、合并症和疾病特征(包括特定突变谱)的的风险适应治疗框架。
要点
- 2022年发布了一套更新和一套新的分类系统,均强调将分子分析整合到日常实践中。
- 欧洲白血病网2022风险分类整合了新的分子发现和近期试验结果,并强调基于连续可测量残留病评估的动态风险。
- 诊断和治疗复杂性以及新获批药物的可用性要求采用细致的治疗算法,整合患者治疗目标、合并症和疾病特征包括特定突变谱。
核心结论
- AML的诊断、预后和治疗格局因对病理生理学的理解改善、测量技术进步和至少10种近期获批疗法而得到重塑。
- 我们建议的框架仅代表讨论的开始。
研究设计与样本
- 本文为综述,未报告检索范围。
主要发现
- 2022年发布了一套更新和一套新的分类系统,均强调将分子分析整合到日常实践中。
- 国际共识分类与之前2016年WHO系统的主要修订之间的差异为护理和临床研究提供了挑战和机遇。
- 欧洲白血病网2022风险分类整合了新的分子发现和近期试验结果,并强调基于连续可测量残留病评估的动态风险。
- 如何将我们新兴的测量少量潜在恶性髓系细胞的能力用于治疗决策存在争议。
关键数值与推荐
- 欧洲白血病网2022风险分类整合了新的分子发现和近期试验结果,并强调基于连续可测量残留病评估的动态风险。
临床怎么用
- 诊断和治疗复杂性以及新获批药物的可用性要求采用细致的治疗算法,该算法应整合患者治疗目标、合并症和疾病特征包括患者AML的特定突变谱。
- 我们建议的框架仅代表讨论的开始。
局限性
- 如何将我们新兴的测量少量潜在恶性髓系细胞的能力用于治疗决策存在争议。
- 我们建议的框架仅代表讨论的开始。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding. An improved understanding of pathophysiology, improvements in measurement technology and at least 10 recently approved therapies have led to revamping the diagnostic, prognostic, and therapeutic landscape of AML. DIAGNOSIS: One updated and one new classification system were published in 2022, both emphasizing the integration of molecular analysis into daily practice. Differences between the International Consensus Classification and major revisions from the previous 2016 WHO system provide both challenges and opportunities for care and clinical research. RISK ASSESSMENT AND MONITORING: The European Leukemia Net 2022 risk classification integrates knowledge from novel molecular findings and recent trial results, as well as emphasizing dynamic risk based on serial measurable residual disease assessment. However, how to leverage our burgeoning ability to measure a small number of potentially malignant myeloid cells into therapeutic decision making is controversial. RISK ADAPTED THERAPY: The diagnostic and therapeutic complexity plus the availability of newly approved agents requires a nuanced therapeutic algorithm which should integrate patient goals of care, comorbidities, and disease characteristics including the specific mutational profile of the patient's AML. The framework we suggest only represents the beginning of the discussion.
引用
- Shimony S, Stahl M, Stone RM, et al. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023. PMID: 36594187. doi:10.1002/ajh.26822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。